Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
(BIDU - Get Report) rated new Buy at Jefferies. $200 price target. Company is a market leader with limited competition.
(CMA - Get Report) rated new Market Perform at Morgan Keegan. $38 price target. Visibility remains low for potential loan growth.
(FAST - Get Report)
upgraded at UBS from Neutral to Buy. $72 price target. Estimates also boosted, as sales growth can drive margin expansion.
upgraded at Goldman to Buy, Goldman Sachs said. $80 price target. Industry should benefit from improving macro trends.
upgraded to Outperform at Wells Fargo. Expecting a more robust Esbriet launch.
upgraded at from Sell to Neutral, Goldman Sachs said. $80 price target. Company can move past the FDA issue and should continue to realize synergies from recent deals.
upgraded at ThinkEquity from Hold to Buy. $48 price target. Guidance confirms recent checks that show demand can recover.
upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $40 price target. Company pre-announced to the upside, easing some demand concerns.
(SIRO - Get Report)
rated new Buy at Goldman. Company was also addded to the Conviction Buy list. Company is leverage to increased spending on high-tech equipment. $61 price target.
(SUN - Get Report)
downgraded at Benchmark from Hold to Sell, Benchmark Company said. $34 price target. Company is facing an unfavorable settlement for coke pricing.
(XRAY - Get Report)
rated new Neutral at Goldman Sachs. $39 price target. Stock is already pricing in improving industry growth.
End of report.